• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    10/4/23 1:31:13 PM ET
    $BCLI
    $GRTS
    $HSTO
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email

    Gainers

    • Vivos Therapeutics (NASDAQ:VVOS) shares moved upwards by 105.4% to $0.38 during Wednesday's regular session. The current volume of 201.6 million shares is 13196.4% of Vivos Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $11.3 million.
    • Nuvalent (NASDAQ:NUVL) shares moved upwards by 31.37% to $55.73. Trading volume for this security as of 13:30 EST is 3.9 million, which is 1095.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 billion.
    • Histogen (NASDAQ:HSTO) stock moved upwards by 27.11% to $0.65. Histogen's stock is trading at a volume of 2.3 million shares as of 13:30 EST. This is 1121.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.7 million.
    • MiNK Therapeutics (NASDAQ:INKT) stock increased by 24.57% to $1.09. Trading volume for MiNK Therapeutics's stock is 83.9K as of 13:30 EST. This is 126.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $37.6 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares rose 18.94% to $0.2. As of 13:30 EST, this security is trading at a volume of 37.9 million shares, making up 6171.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.1 million.
    • Gritstone Bio (NASDAQ:GRTS) shares increased by 18.18% to $2.4. As of 13:30 EST, this security is trading at a volume of 9.6 million shares, making up 838.8% of its average full-day volume over the last 100 days. The company's market cap stands at $223.3 million.

    Losers

    • Inhibikase Therapeutics (NASDAQ:IKT) shares fell 33.2% to $0.93 during Wednesday's regular session. The current volume of 9.1 million shares is 18995.5% of Inhibikase Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $5.0 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) shares declined by 32.56% to $1.16. The current volume of 152.2K shares is 3202.4% of Protagenic Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $5.0 million.
    • Standard BioTools (NASDAQ:LAB) stock decreased by 24.06% to $2.05. As of 13:30 EST, Standard BioTools's stock is trading at a volume of 3.0 million, which is 1205.8% of its average full-day volume over the last 100 days. The company's market cap stands at $161.9 million.
    • Nuwellis (NASDAQ:NUWE) stock declined by 19.69% to $1.02. Trading volume for Nuwellis's stock is 160.8K as of 13:30 EST. This is 169.3% of its average full-day volume over the last 100 days. The company's market cap stands at $1.9 million.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) shares fell 19.49% to $1.24. The market value of their outstanding shares is at $7.1 million.
    • MSP Recovery (NASDAQ:LIFW) stock decreased by 18.84% to $0.2. Trading volume for MSP Recovery's stock is 13.8 million as of 13:30 EST. This is 37.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $67.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $GRTS
    $HSTO
    $IKT

    CompanyDatePrice TargetRatingAnalyst
    Nuvalent Inc.
    $NUVL
    3/30/2026$116.00Overweight
    Wells Fargo
    Inhibikase Therapeutics Inc.
    $IKT
    3/4/2026$4.00Buy
    Ladenburg Thalmann
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Inhibikase Therapeutics Inc.
    $IKT
    12/26/2025$8.00Buy
    H.C. Wainwright
    Inhibikase Therapeutics Inc.
    $IKT
    12/11/2025$4.00Overweight
    Cantor Fitzgerald
    Nuvalent Inc.
    $NUVL
    11/24/2025Buy
    Truist
    Nuvalent Inc.
    $NUVL
    11/12/2025$126.00Buy
    Canaccord Genuity
    Nuvalent Inc.
    $NUVL
    10/16/2025$115.00Buy
    Stifel
    More analyst ratings

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

    NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA. Presentation Details: Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDSPresenter: Terese C. Hammond, MD; Progr

    4/2/26 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 occurring May 15-20, 2026 in Orlando, Florida. The abstract, titled "Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection," highlights a novel

    4/1/26 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Nuvalent with a new price target

    Wells Fargo initiated coverage of Nuvalent with a rating of Overweight and set a new price target of $116.00

    3/30/26 8:25:33 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $4.00

    3/4/26 8:37:45 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Inhibikase Therapeutics with a new price target

    BofA Securities initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $6.00

    1/21/26 8:55:17 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Noci Darlene

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    4/1/26 4:30:32 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Miller Deborah Ann

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    3/30/26 5:31:51 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Balcom Alexandra

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    3/26/26 4:30:12 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    SEC Filings

    View All

    Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Nuwellis, Inc. (0001506492) (Filer)

    4/1/26 4:45:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.

    10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 5:26:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by MiNK Therapeutics Inc.

    10-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

    3/31/26 4:49:08 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/26/25 4:58:37 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Large owner Sands Capital Life Sciences Pulse Fund Ii, L.P. bought $2,999,999 worth of shares (2,068,965 units at $1.45) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    11/24/25 3:47:02 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Protagenic Therapeutics Inc.

    SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

    11/14/24 5:19:32 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $GRTS
    $HSTO
    $IKT
    Financials

    Live finance-specific insights

    View All

    MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

    ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncologyNIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026Keystone Symposia data report iNKT depletion in end-stage Pulmonary Fibrosis (IPF); underscores pipeline expansionPortfolio focused on high-value immune restoration with multiple 2026 clinical catalysts NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT),

    3/31/26 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026. The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio. The update follows several recent corporate

    3/17/26 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care